Cytokine profile in patients with granulomatosis and polyangiitis (Wegener’s disease). Literature review
Lopatina I.A.1, Moiseev S.V.1, Mezentseva M.V.2
1 Sechenov University, Moscow
2 National Research Center of Epidemiology and Microbiology n. a. N.F.Gamaley, Moscow
Granulomatosis with polyangiitis (GPA) is a systemic vasculitis, characterized by the development of granulomatous inflammation and necrotizing vasculitis of small vessels with a predominant lesion of the upper respiratory tract, lungs and kidneys. GPA remains one of the most severe and prognostically unfavorable forms of systemic vasculitis. In recent years, there has been a trend towards an increase in the number of patients with GPA. On the one hand, immunosuppressive treatment improves a long-term prognosis, on the other hand the incidence of the disease can really rise. The study of the role of cytokines in the development of the immunopathological process in patients with GPA is justified from a practical point of view in connection with the possibility of using genetically engineered biological preparations in this group of patients. The investigation of cytokines in relapse and remission GPA detects the potential target of the therapeutic intervention in case of exacerbation of the disease. Besides that, for the present time it is important to know the cytokine changes in generalized and localized GPA, since in the absence of treatment, more than 80% of patients with generalized form of GPA die within a year. In foreign literature there are conflicting data about immunopathological mechanisms and prevalence and activity validation methods in GPA patients. In native literature there are data about cytokines in ANCA- associated vasculitis (granulomatosis with polyangiitis (Wegener’s disease), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis)
Key words: cytokines, immune response, granulomatosis with polyangiitis, relapse, remission.
For citation: Lopatina I.A., Moiseev S.V., Mezentseva M.V. Cytokine profile in patients with granulomatosis and polyangiitis (Wegener’s disease). Literature review // RMJ. 2018. № 1(II). P. 113–117.
References
1. Новиков П.И., Семенкова Е.Н., Моисеев С.В. Современная номенклатура системных васкулитов // Клиническая фармакология и терапия. 2013. Т.22. №1. С.70–74 [Novikov P.I., Semenkova E.N., Moiseev S.V. Sovremennaja nomenklatura sistemnyh vaskulitov // Klinicheskaja farmakologija i terapija. 2013. T.22. №1. S.70–74 (in Russian)].
2. Семенкова Е.Н. Системные некротизирующие васкулиты. М.: Русский врач. 2001. 48 с. [Semenkova E.N. Sistemnye nekrotizirujushhie vaskulity. M.: Russkij vrach. 2001. 48 s. (in Russian)].
3. Моисеев С.В., Новиков П.И., Мешков А.Д., Иваницкий Л.В. АНЦА-ассоциированные васкулиты: спорные вопросы классификации, диагностики и оценки активности и современные подходы к лечению // Клиническая фармакология и терапия. 2014. Т.23. №1. С.44–50 [Moiseev S.V., Novikov P.I., Meshkov A.D., Ivanickij L.V. ANCA-associirovannye vaskulity: spornye voprosy klassifikacii, diagnostiki i ocenki aktivnosti i sovremennye podhody k lecheniju // Klinicheskaja farmakologija i terapija. 2014. T.23. №1. S.44–50 (in Russian)].
4. Buraa Kubaisi, Khawla Abu Samra, C. Stephen Foster. Granulomatosis with polyangiitis (Wegener’s disease): An updated review of ocular disease manifestations // Intractable Rare Dis Res. 2016. Vol. 5. №2. P.61–69.
5. Mohammad A.J., Jacobsson L.T., Westman K.W. et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa // Rheumatology (Oxford, England). 2009. Vol. 48. P.1560–1565.
6. Кетлинский С.А., Симбирцев А.С. Цитокины. СПб.: Фолиант. 2008. 552 с. [Ketlinskij S.A., Simbircev A.S. Citokiny. SPb.: Foliant. 2008. 552 s. (in Russian)].
7. Симбирцев А.С. Цитокины: классификация и биологические функции // Цитокины и воспаление. 2004. Т.3. №2. С.16–23 [Simbircev A.S. Citokiny: klassifikacija i biologicheskie funkcii // Citokiny i vospalenie. 2004. T.3. №2. S.16–23 (in Russian)].
8. Хаитов Р.М. Иммунология: учебник для студентов медицинских вузов. М.: ГЭОТАР-Медиа. 2006. 320 с. [Haitov R.M. Immunologija: uchebnik dlja studentov medicinskih vuzov. M.: GJeOTAR-Media. 2006. 320 s. (in Russian)].
9. Воробьев А.А., Быков А.С., Караулов А.В. Иммунология и аллергология. Цветной атлас. М.: Практическая медицина. 2006. 51 с. [Vorob’ev A.A., Bykov A.S., Karaulov A.V. Immunologija i allergologija. Cvetnoj atlas. M.: Prakticheskaja medicina. 2006. 51 s. (in Russian)].
10. Якушенко Е.В., Лопатникова Ю.А., Сенников С.В. Интерлейкин 18 и его роль в иммунном ответе // Медицинская иммунология. 2005. Т.7. №4. С.355–364 [Jakushenko E.V., Lopatnikova Ju.A., Sennikov S.V. Interlejkin 18 i ego rol’ v immunnom otvete // Medicinskaja immunologija. 2005. T.7. №4. S.355–364 (in Russian)].
11. Мухин Н.А., Новиков П.И., Моисеев С.В. и др. Эффективность и безопасность генно-инженерных биологических препаратов у пациентов с ревматоидным артритом и другими ревматическими заболеваниями (проспективное неконтролируемое исследование) // Клиническая фармакология и терапия. 2012. Т.21. №5. С.25–32 [Muhin N.A., Novikov P.I., Moiseev S.V. i dr. Jeffektivnost’ i bezopasnost’ genno-inzhenernyh biologicheskih preparatov u pacientov s revmatoidnym artritom i drugimi revmaticheskimi zabolevanijami (prospektivnoe nekontroliruemoe issledovanie) // Klinicheskaja farmakologija i terapija. 2012. T.21. №5. S.25–32 (in Russian)].
12. С.В. Долгих, В.И. Мазуров. Клинико-иммунологическая характеристика системных васкулитов // Аллергология и иммунология. 2009. Т.10. №2. С.224 [S.V. Dolgih, V.I. Mazurov. Kliniko-immunologicheskaja harakteristika sistemnyh vaskulitov // Allergologija i immunologija. 2009. T.10. №2. S.224 (in Russian)].
13. Reinhold-Keller E., Lamprecht P., Feller A.C., Gross W.L. Polyarthritis following interferon alpha treatment in a patient with localized Wegener’s granulomatosis // Clin Exp Rheumatol. 2001. Vol. 19. P.227–228.
14. Müller A., Trabandt A., Gloeckner-Hofmann K. et al. Localized Wegener’s granulomatosis: predominance of CD26 and IFN-gamma expression // J Pathol. 2000. Vol. 192. №1. P. 113–120.
15. Csernok E., Trabandt A., Müller A. et al. Cytokine profiles in Wegener’s granulomatosis: Predominance of type 1 (Th1) in the granulomatous inflammation // Arthritis Rheum. 1999. Vol. 42. №4. P.742–750.
16. Tomer Y., Barak V., Gilburd B., Shoenfeld Y. Cytokines in experimental autoimmune vasculitis: evidence for a Th2 type response // Clin Exp Rheumatol. 1999. Vol. 17. №5. P.521–526.
17. С.В. Долгих, В.И. Мазуров. Клинико-иммунологическая характеристика системных васкулитов // Аллергология и иммунология. 2009. Т.10. №2. С.224 [S.V. Dolgih, V.I. Mazurov. Kliniko-immunologicheskaja harakteristika sistemnyh vaskulitov // Allergologija i immunologija. 2009. T.10. №2. S.224 (in Russian)].
18. Balding C.E., Howie A.J., Drake-Lee A.B., Savage C.O. Th2 dominance in nasal mucosa in patients with Wegener’s granulomatosis // Clin Exp Immunol. 2001. Vol. 125. №2. P.332–339.
19. Fagin U., Csernok E., Müller A. et. al. Distinct proteinase 3-induced cytokine patterns in Wegener´s granulomatosis, Churg-Strauss syndrome, and healthy controls. // Clin Exp Rheumatol. 2011. Vol. 29. №64. P.57–62.
20. Tomasson G., Lavalley M., Tanriverdi K. et. al. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Relationship between markers of platelet activation and inflammation with disease activity in Wegener’s granulomatosis // J Rheumatol. 2011. Vol. 38. №6. P.1048–1054.
21. Abdulahad W.H., Stegeman C.A., Limburg P.C., Kallenberg C.G. Skewed distribution of Th17 lymphocytes in patients with Wegener’s granulomatosis in remission // Arthritis Rheum. 2008. Vol. 58. №7. P.2196–2205.
22. Perkins G.D., Nathani N., McAuley D.F. et al. In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury // Thorax. 2007. Vol. 62. P.36–42.
23. Rani L., Minz R.W., Sharma A. Predominance of PR3 specific immune response and skewed Th17 vs. T-regulatory milieu in activegranulomatosis with polyangiitis // Cytokine. 2015. Vol. 71. №2. P.261–267.
24. Novick D., Elbirt D., Dinarello C.A. et. al. Interleukin-18 binding protein in the sera of patients with Wegener’s granulomatosis // J Clin Immunol. 2009. Vol. 29. №1. P.38–45.
25. Dejica D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy // Roum Arch Microbiol Immunol. 2001. Vol. 60. №3. P.183–201.
26. Hattar K., Oppermann S., Ankele C. c-ANCA-induced neutrophil-mediated lung injury: a model of acute Wegener’s granulomatosis // Eur Respir J. 2010. Vol. 36. №1. P.187–195.
27. Hattar K., Bickenbach A., Csernok E. Wege1ner’s granulomatosis: antiproteinase 3 antibodies induce monocyte cytokine and prostanoid release-role of autocrine cell activation // J Leukoc Biol. 2002. Vol. 71. №6. P.996–1004.
28. Uehara A., Sato T., Iwashiro A., Yokota S. PR3-ANCA in Wegener’s granulomatosis prime human mononuclear cells for enhanced activation via TLRs and NOD1/2 // Diagn Pathol. 2009. Vol. 14. №4. P.23.
29. Park J., Lee E.B., Song Y.W. Decreased tumour necrosis factor-α production by monocytes of granulomatosis with polyangiitis // Scand J Rheumatol. 2014. Vol. 43. №5. P.403–408.
30. Holmén C., Elsheikh E., Stenvinkel P. Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement // J Am Soc Nephrol. 2005. Vol. 16. №10. P.3110–3120.
31. Richter A.G., Perkins G.D., Chavda A. et al. Neutrophil chemotaxis in granulomatosis with polyangiitis (Wegener’s) and idiopathic pulmonary fibrosis // Eur Respir J. 2011. Vol. 38. №5. P.1081–1088.
32. Schnabel A., Csernok E., Braun J. et al. Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener’s granulomatosis // Am J Respir Crit Care Med. 2000. Vol.161. P.399–405.
33. Wagner J.G., Roth R.A. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature // Pharmacol Rev. 2000. Vol. 52. P.349–374.
34. Strieter R.M., Gomperts B.N, Keane M.P. The role of CXC chemokines in pulmonary fibrosis // J Clin Invest. 2007. Vol. 117. P.549–556.
35. Perkins G.D., Nathani N., McAuley D.F. et al. In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury // Thorax. 2007. Vol. 62. P.36–42.
36. Torheim E.A., Yndestad A., Bjerkeli V. et al. Increased expression of chemokines in patients with Wegener’s granulomatosis — modulating effects of methylprednisolone in vitro // Clin Exp Immunol. 2005. Vol. 140. P.376–383.
37. Ohta N., Fukase S., Aoyagi M. Serum levels of soluble adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with Wegener’s granulomatosis // Auris Nasus Larynx. 2001. Vol. 28. P.311–314.
38. Stone J.H. Wegener’s Granulomatosis Etanercept Trial Research Group. Limited Versus Severe Wegener’s Granulomatosis Baseline Data on Patients in the Wegener’s Granulomatosis Etanercept Trial. // Arthritis Rheum. 2003. Vol. 48. №8. P.2299–2309.
39. Новиков П.И., Моисеев С.В. Рекомендации Британского ревматологического общества / Британской ассоциации ревматологов по лечению АНЦА-ассоциированных васкулитов у взрослых // Клиническая фармакология и терапия. 2014. T.5. C.97–104 [Novikov P.I., Moiseev S.V. Rekomendacii Britanskogo revmatologicheskogo obshhestva / Britanskoj associacii revmatologov po lecheniju ANCA-associirovannyh vaskulitov u vzroslyh // Klinicheskaja farmakologija i terapija. 2014. T.5. C.97–104 (in Russian)].
40. Stone J.H., Uhlfelder M.L., Hellmann D.B. et al. Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-month open-label trial to evaluate safety // Arthritis Rheum. 2001. Vol. 44. P.1149–1154.
41. Bartolucci P., Ramanoelina J., Cohen P. et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients // Rheumatology (Oxford). 2002. Vol. 41. P.1126–1132.
42. Lamprecht P., Voswinkel J., Lilienthal T. et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis // Rheumatology (Oxford). 2002. Vol. 41. P.1303–1307.
43. Booth A.D., Bacon P.A., Griffith M.E. et al. Infliximab in ANCA-associated vasculitis: the «ACTIVE» trial // Kidney Blood Press Res. 2003. Vol. 26. P.292–293.
44. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis // N Engl J Med. 2005. Vol. 352. №4. P.351–361.
45. Henderson C.F., Seo P. Biologic agents in systemic vasculitis // Int J Clin Rheumtol. 2011. Vol. 6. №4. P.453–462.
46. Lamprecht P., Kumanovics G., Mueller A. et al. Elevated monocytic IL-12 and TNF-α production in Wegener’s granulomatosis is normalized by cyclophosphamide and corticosteroid therapy. // Clin Exp Immunol. 2002. Vol. 128. №1. P.181–186.
47. Новиков П.И., Зыкова А.С., Смитиенко И.О., Моисеев С.В. Лечение АНЦА-ассоциированных васкулитов: рекомендации EULAR/ERA-EDTA 2016 г. // Клиническая фармакология и терапия. 2017. 26. №1. C.1–8 [Novikov P.I., Zykova A.S., Smitienko I.O., Moiseev S.V. Lechenie ANCA-associirovannyh vaskulitov: rekomendacii EULAR/ERA-EDTA 2016 g. // Klinicheskaja farmakologija i terapija. 2017. 26. №1. C.1–8 (in Russian)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
